open access

Vol 51, No 3 (2017)
Original research articles
Submitted: 2016-11-29
Get Citation

Brain-derived neurotrophic factor levels under chronic natalizumab treatment in multiple sclerosis. A preliminary report

Vitalie Văcăraş, Zoltán Zsigmond Major, Anca Dana Buzoianu
DOI: 10.1016/j.pjnns.2017.03.002
·
Neurol Neurochir Pol 2017;51(3):221-226.

open access

Vol 51, No 3 (2017)
Original research articles
Submitted: 2016-11-29

Abstract

Aim of the study

Our main purpose was to investigate if the chronic treatment with the disease-modifying drug natalizumab shows quantifiable effect on BDNF levels in multiple sclerosis patients.

Materials and Methods

BDNF plasma concentration was evaluated using enzyme-linked immunosorbent assay in healthy individuals, not treated multiple sclerosis patients and patients treated with natalizumab.

Results

Multiple sclerosis patients have a significantly lower amount of peripheral BDNF than healthy individuals. Patients treated with natalizumab have significantly higher BDNF levels than not treated patients.

Conclusions

Chronic natalizumab treatment is associated with significantly increased plasma BDNF concentration in multiple sclerosis.

Abstract

Aim of the study

Our main purpose was to investigate if the chronic treatment with the disease-modifying drug natalizumab shows quantifiable effect on BDNF levels in multiple sclerosis patients.

Materials and Methods

BDNF plasma concentration was evaluated using enzyme-linked immunosorbent assay in healthy individuals, not treated multiple sclerosis patients and patients treated with natalizumab.

Results

Multiple sclerosis patients have a significantly lower amount of peripheral BDNF than healthy individuals. Patients treated with natalizumab have significantly higher BDNF levels than not treated patients.

Conclusions

Chronic natalizumab treatment is associated with significantly increased plasma BDNF concentration in multiple sclerosis.

Get Citation

Keywords

BDNF, MS, Natalizumab

About this article
Title

Brain-derived neurotrophic factor levels under chronic natalizumab treatment in multiple sclerosis. A preliminary report

Journal

Neurologia i Neurochirurgia Polska

Issue

Vol 51, No 3 (2017)

Pages

221-226

DOI

10.1016/j.pjnns.2017.03.002

Bibliographic record

Neurol Neurochir Pol 2017;51(3):221-226.

Keywords

BDNF
MS
Natalizumab

Authors

Vitalie Văcăraş
Zoltán Zsigmond Major
Anca Dana Buzoianu

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl